Mayne Pharma Group (ASX:MYX) reported Wednesday a fiscal first-half loss of AU$0.323 per diluted share, narrowing from AU$0.878 per diluted share a year earlier.
Revenue for the six months ended Dec. 31, 2024, was AU$213.1 million, up 13% from AU$187.9 million a year earlier.
The company said it expects to grow underlying earnings before interest, taxes, depreciation, and amortization in the second fiscal half via revenue growth and cost leverage.
The firm did not declare a dividend for the reported half-year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。